Once-weekly dosing of Kyprolis improves PFS vs. twice-weekly option

Amgen Inc. (NASDAQ:AMGN) reported interim data from the Phase III ARROW trial in 478 patients with relapsed and refractory multiple myeloma

Read the full 213 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE